SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. __)1
Ampersand Medical Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
032065104
--------------------------------------------------------------------------------
(CUSIP Number)
June 1, 2000
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
--------------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, SEE the
NOTES).
<PAGE>
---------------------------- ---------------------------
CUSIP No. 032065104 13G Page 2 of 5 Pages
--------- --- ---
---------------------------- ---------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Seaside Partners, L.P.
------------------------------- -------------------------
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |X|
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------
--------------------------------------------------------------------------------
NUMBER OF
SHARES 5 SOLE VOTING POWER 4,207,500
--------------
------------------------------------------------------------------
BENEFICIALLY
OWNED BY 6 SHARED VOTING POWER N/A
------------------------------------------------------------------
EACH
REPORTING 7 SOLE DISPOSITIVE POWER 4,207,500
--------------
------------------------------------------------------------------
PERSON WITH 8 SHARED DISPOSITIVE POWER N/A
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,207,500
--------------
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 14.5%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON* PN
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
ITEM 1(A). NAME OF ISSUER:
The issuer of the securities to which this statement relates is
Ampersand Medical Corporation, a Delaware corporation.
ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
The issuer's principal executive offices are located at 900 North
Franklin Street, Suite 210, Chicago, IL 60610.
ITEM 2(A). NAME OF PERSON FILING:
The person filing is Seaside Partners, L.P.
ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
The principal business office is 623 Ocean Avenue, Sea Girt, New
Jersey 08750.
ITEM 2(C). CITIZENSHIP:
Not applicable
ITEM 2(D). TITLE OF CLASS OF SECURITIES:
The title of the class of securities is common stock, $0.01 par
value.
Item 2(e). CUSIP Number:
The CUSIP number is 032065104.
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B)
OR (C), CHECK WHETHER THE PERSON FILING IS A:
The filing categories available pursuant to Rule 13d-1(b) are not
applicable to Seaside Partners, L.P.
If this statement is filed pursuant to Rule 13d-1(c), check this
box. |X|
ITEM 4. OWNERSHIP.
(a) The number of shares beneficially owned by Seaside
Partners, L.P. is 4,207,500.
(b) The percent of the class held by Seaside Partners, L.P.
is 14.5%.
(c) (i) Seaside Partners, L..P. has sole power to vote or to
direct the vote of 4,207,500 shares.
(ii) The shared power to vote or to direct the vote of shares
is not applicable.
(iii)Seaside Partners, L.P. has sole power to dispose or to
direct the disposition of 4,207,500 shares.
(iv) The shared power to dispose or to direct the disposition
of shares is not applicable.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
The ownership of five percent or less of a class is not
applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
The ownership of more than five percent on behalf of another
person is not applicable.
<PAGE>
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY.
The identification and classification of the subsidiary which
acquired the security being reported on by the parent holding
company is not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
The identification and classification of members of the group is
not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
The notice of dissolution of a group is not applicable.
ITEM 10. CERTIFICATIONS.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Seaside Partners, L.P.
June 8, 2000 By: /s/ William J. Ritger
------------ ------------------------------
Name: William J. Ritger
Title: Managing Director
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
NOTE. Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
---
parties for whom copies are to be sent.
ATTENTION. Intentional misstatements or omissions of fact constitute
federal criminal violations. (SEE 18 U.S.C. 1001.)